- Home
- OABI vs DHY Comparison
OABI vs DHY Comparison
Compare OABI & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- DHY
- Stock Information
- Founded
- OABI 2012
- DHY 1998
- Country
- OABI United States
- DHY United States
- Employees
- OABI N/A
- DHY N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- DHY Finance/Investors Services
- Sector
- OABI Health Care
- DHY Finance
- Exchange
- OABI Nasdaq
- DHY Nasdaq
- Market Cap
- OABI 198.2M
- DHY 211.3M
- IPO Year
- OABI N/A
- DHY N/A
- Fundamental
- Price
- OABI $2.18
- DHY $2.14
- Analyst Decision
- OABI Strong Buy
- DHY
- Analyst Count
- OABI 3
- DHY 0
- Target Price
- OABI $7.00
- DHY N/A
- AVG Volume (30 Days)
- OABI 854.4K
- DHY 569.1K
- Earning Date
- OABI 08-07-2025
- DHY 01-01-0001
- Dividend Yield
- OABI N/A
- DHY 9.10%
- EPS Growth
- OABI N/A
- DHY N/A
- EPS
- OABI N/A
- DHY N/A
- Revenue
- OABI $26,744,000.00
- DHY N/A
- Revenue This Year
- OABI N/A
- DHY N/A
- Revenue Next Year
- OABI $45.65
- DHY N/A
- P/E Ratio
- OABI N/A
- DHY N/A
- Revenue Growth
- OABI 27.07
- DHY N/A
- 52 Week Low
- OABI $1.22
- DHY $1.77
- 52 Week High
- OABI $4.96
- DHY $2.08
- Technical
- Relative Strength Index (RSI)
- OABI 72.48
- DHY 65.11
- Support Level
- OABI $1.79
- DHY $2.11
- Resistance Level
- OABI $1.73
- DHY $2.00
- Average True Range (ATR)
- OABI 0.11
- DHY 0.02
- MACD
- OABI 0.04
- DHY 0.00
- Stochastic Oscillator
- OABI 93.97
- DHY 87.67
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.